公开(公告)号：WO2023091968A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079987

申请日：2022-11-16

Applicant: DISC MEDICINE, INC. ,  ABBVIE DEUTSCHLAND GMBH & CO. KG ,  ABBVIE INC.

Inventor： MACDONALD, Brian ,  QUISEL, John ,  SAVAGE, Will ,  YANG, Hua ,  YU, Jonathan ,  WU, Min ,  BECONI, Maria ,  PEREZ, Jennifer, M. ,  MUELLER, Bernhard ,  POPP, Andreas

IPC: A61P7/06 ,  C07K16/22 ,  C07K16/28 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

Abstract: Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and/or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

公开(公告)号：WO2023091951A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079966

申请日：2022-11-16

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： LO, Roger S. ,  YANG, Zhentao

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/18

Abstract: Described are methods for enhancing cancer immune surveillance and the efficacy of the treatment of melanoma or non-melanoma cancers such as pancreatic or colorectal cancers, particularly by controlling cancer cell-surface PD-L1/L2 and the E3 ligase ITCH. Also described are methods of inhibiting an adaptive immune resistance response to anti-immune checkpoint protein therapy in a subject. As described herein, the efficacy of MAPK inhibitor therapy is increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1/L2. As further demonstrated herein, the efficacy of anti-PD-1/L1 therapy is also increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1/L2.

公开(公告)号：WO2023091865A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079442

申请日：2022-11-08

Applicant: CELLDEX THERAPEUTICS, INC. ,  BIOSION, INC.

Inventor： KELLER, Tibor ,  GOLDSTEIN, Joel ,  MURPHY, Michael ,  O'NEILL, Thomas ,  VITALE, Laura, A. ,  CHEN, Mingjiu

IPC: C07K16/28 ,  A61K39/00

Abstract: Provided herein are novel anti-ILT4 and anti-PD- 1 bispecific constructs, as well as corresponding compositions. Methods of inducing or enhancing an immune response, and methods of treating cancer, by administering the constructs or compositions also are described.

公开(公告)号：WO2023088221A1

公开(公告)日：2023-05-25

申请号：PCT/CN2022/131820

申请日：2022-11-15

Applicant: SUZHOU TRANSCENTA THERAPEUTICS CO., LTD. ,  TRANSCENTA HOLDING LIMITED ,  TRANSCENTA THERAPEUTICS, INC.

Inventor： QIAN, Xueming ,  YAO, Xinlai ,  GUO, Huanhuan ,  TENG, Fei ,  YI, Wei

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395

Abstract: Provided are combination therapies of a CLDN 18.2 antagonist and a PD-1/PD-L1 axis inhibitor for subjects having expression of CLDN 18.2 and having low or no expression of PD-L1 in a disease tissue (e.g., tumor tissue) obtained from the subject.

公开(公告)号：WO2023087344A1

公开(公告)日：2023-05-25

申请号：PCT/CN2021/132785

申请日：2021-11-24

Applicant: 杭州翰思生物医药有限公司

Inventor： 柯航 ,  张发明 ,  彭飞宇

IPC: C07K16/46 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

Abstract: 提出了一种重组抗体或抗原结合片段，该重组抗体包括：抗PD-1的抗体；以及人抗VEGF的抗体、人VEGF诱捕蛋白或人抗VEGFR的抗体，所述抗PD-1的抗体包含重链和轻链，所述人抗VEGF的抗体的N端与所述抗PD-1的抗体的重链的C端相连；所述人VEGF诱捕蛋白的N端与所述抗PD-1的抗体的重链的C端相连；或所述人VEGF诱捕蛋白的C端与所述抗PD-1的抗体的重链的N端相连；所述人抗VEGFR的抗体的N端与所述抗PD-1的抗体的重链的C端相连。

公开(公告)号：WO2023086897A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079656

申请日：2022-11-10

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： RADER, Christoph ,  CYR, Matthew Gerard

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/02

Abstract: The invention provides antibodies, antibody -based fragments or antibody fragments (antigen-binding fragments), as well as derivative molecules such as bispecific T- cell engagers, antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize Siglec-6 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.

公开(公告)号：WO2023086835A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079568

申请日：2022-11-09

Applicant: SENSEI BIOTHERAPEUTICS, INC.

Inventor： PIERCE, Robert ,  VAN DER HORST, Edward H. ,  THISTED, Thomas ,  BOLAND, Nadthakarn ,  NIELSON, Nels

IPC: A61P35/00 ,  C07K16/28

Abstract: Provided herein are antibody molecules that bind specifically to VISTA and antigen-binding portions thereof and related compositions, nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

公开(公告)号：WO2023086772A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079416

申请日：2022-11-07

Applicant: XENCOR, INC. ,  BERNETT, Matthew ,  ZHANG, Tian ,  PONG, Erik ,  AVERY, Kendra ,  DESJARLAIS, John

Inventor： BYKOVA, Katrina ,  FABER, Matthew

IPC: C07K16/28

Abstract: Provided herein are bispecific antibodies that bind to B7H3 and NKG2D (e.g., antibodies having Fab-scFv-Fc, Fab2-scFv-Fc, mAb-scFv and stackFab2-scFv-Fc formats) or antigen binding fragments thereof. Also provided herein are polynucleotide sequences encoding a chain and/or a CDR of a bispecific antibody of the disclosure; and vectors and cells comprising such polynucleotide sequences. Also provided herein are methods of treating cancer in a subject with a bispecific antibody of the disclosure.

公开(公告)号：WO2023085978A1

公开(公告)日：2023-05-19

申请号：PCT/RU2022/050351

申请日：2022-11-07

Applicant: JOINT STOCK COMPANY «BIOCAD»

Inventor： BELIASNIKOVA, Alina Valerevna ,  KYTMANOVA, Olga Leonidovna ,  CHERNYSHOVA, Darya Olegovna ,  SHCHEMELEVA, Mariia Aleksandrovna ,  AFREMOVA, Anastasiia Isaevna ,  MOROZOV, Dmitry Valentinovich

IPC: C07K16/28 ,  C12N15/24 ,  C12N15/63 ,  C12N15/85 ,  A61K39/395 ,  A61P17/00 ,  A61P29/00 ,  A61P37/00

Abstract: The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to IL-4Rα (interleukin-4 receptor subunit alpha). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods for treating diseases or disorders mediated by IL-4Rα, uses of the antibodies or pharmaceutical compositions thereof for treating diseases or disorders mediated by IL-4Rα, and uses of the antibodies and other therapeutically active compounds for treating diseases or disorders mediated by IL-4Rα.

公开(公告)号：WO2023083868A1

公开(公告)日：2023-05-19

申请号：PCT/EP2022/081274

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： SAHIN, Ugur ,  HASSAN, Hariz Iskandar Bin ,  STROBL, Stefan ,  RÖSEMANN, Roman

IPC: A61K31/4745 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/395 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/28

Abstract: The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.